Correction

November 6, 1997

Correction Correction

An article on SIBIA Neurosciences Inc. in BioWorld Today, Nov. 5, 1997, should have said the company has $37.76 million in cash.

No Comments

You must login or register in order to post a comment.

Today's news in brief

BioWorld

BioWorld briefs for Aug. 7.

Celltrion doubles pace for COVID-19 antibody treatment CT-P59

BioWorld

HONG KONG – Incheon, South Korea-based Celltrion Inc. is rapidly advancing CT-P59, its antiviral antibody treatment for the COVID-19 virus, after receiving its...

Potential COVID-19 cell therapy treatments in development

Cell therapy

Biopharma companies that are focused on cell therapies have reported promising clinical trial results in their ability to treat acute respiratory distress...

With new rapid test, Sorrento expands COVID portfolio

BioWorld MedTech

VANCOUVER – Sorrento Therapeutics Inc., which is working to build a comprehensive lineup of COVID-19 products, has in-licensed a self-contained test for...

Glenmark’s phase III favipiravir study finds drug speeds clinical improvement for some patients

Clinical

HONG KONG – Mumbai, India-headquartered Glenmark Pharmaceuticals Ltd. have released statistically significant top-line results from a phase III trial showing that...

Correction

Related Articles

Report Abusive Comment